Litigation Details for MITSUBISHI TANABE PHARMA CORPORATION v. SANDOZ INC. (D.N.J. 2017)

« Back to Dashboard

MITSUBISHI TANABE PHARMA CORPORATION v. SANDOZ INC. (D.N.J. 2017)

Docket		Date Filed	2017-07-20
Court	District Court, D. New Jersey	Date Terminated
Cause	15:1126 Patent Infringement	Assigned To	Freda L. Wolfson
Jury Demand	None	Referred To
Patents	7,943,788; 8,222,219; 8,785,403
Link to Docket	External link to docket

Details for MITSUBISHI TANABE PHARMA CORPORATION v. SANDOZ INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-20	173	Opinion	infringement of U.S. Patent Nos. 7,943,788 (“the ’788 patent), 8,222,219 (“the ’219 patent), and 8,785,403… (“the ’403 patent”) (collectively, “the patents-in-suit”). Compl. at ¶ 10. The patents-in-suit are… B. Local Patent Rules Pursuant to the Local Patent Rules for the District of…Local Patent Rules. Zydus contends that the “priority date” disclosure required by Local Patent Rule….D. Cal. July 17, 2015) (“Patent L.R. 3-1(f) particularly requires a patent holder to assert a specific	External link to document

Mitsubishi Tanabe Pharma Corporation v. Sandoz Inc. Litigation Summary and Patent Analysis

Last updated: September 26, 2026

Mitsubishi Tanabe Pharma Corporation v. Sandoz Inc., No. 3:17-cv-05319-FLW-DEA, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of New Jersey concerning Sandoz’s abbreviated new drug application for a generic canagliflozin product. The case implicated Mitsubishi Tanabe’s canagliflozin patent estate, including U.S. Patent No. 8,513,202. The action ended without a reported merits judgment establishing patent invalidity or noninfringement.

What drug and patents were involved in Mitsubishi Tanabe v. Sandoz?

The litigation concerned canagliflozin, the sodium-glucose cotransporter 2 inhibitor marketed in the United States as Invokana and used in combination products including Invokamet and Invokamet XR.

Mitsubishi Tanabe developed canagliflozin and held core intellectual-property rights covering the active pharmaceutical ingredient and related C-glucoside compounds. Janssen marketed canagliflozin products in the United States under license and collaboration arrangements involving Mitsubishi Tanabe.

The case was directed principally to the following patent:

Patent	Subject matter	Patent holder or originating assignee	Relevance
U.S. Patent No. 8,513,202	C-glucoside compounds, including canagliflozin-related compounds	Mitsubishi Tanabe Pharma Corporation	Core composition-of-matter protection asserted against Sandoz
Related canagliflozin patents	Compound, crystalline form, formulation, and use claims	Mitsubishi Tanabe and affiliated rights holders	Broader Invokana patent estate, not necessarily all asserted in this action

The ’202 patent was one of the principal composition patents associated with canagliflozin. Its claims were directed to substituted C-glucoside compounds and pharmaceutical uses. The patent’s enforceable term extended into the mid-2020s, subject to patent-term adjustment and any applicable regulatory extension.

What triggered the Hatch-Waxman lawsuit?

Sandoz filed an ANDA seeking FDA approval to market a generic canagliflozin product before expiration of Mitsubishi Tanabe’s patent rights. The ANDA filing included a Paragraph IV certification asserting that the relevant patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

Mitsubishi Tanabe filed suit under the Hatch-Waxman Act. The action was filed in 2017 in the District of New Jersey, within the statutory 45-day period following receipt of Sandoz’s Paragraph IV notice.

A Hatch-Waxman filing generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation is resolved earlier or the court orders otherwise. The stay prevents FDA approval of the ANDA while the patent dispute remains pending, subject to statutory exceptions.

What did Sandoz challenge?

Sandoz’s ANDA challenge placed the following issues in dispute:

1. Whether the proposed generic canagliflozin product would infringe the asserted claims.
2. Whether the asserted claims were invalid for lack of novelty or obviousness.
3. Whether the claims satisfied written-description and enablement requirements.
4. Whether any asserted patent was unenforceable based on inequitable conduct or other equitable defenses.
5. Whether the proposed commercial product fell within the scope of the patent claims.

The central commercial issue was whether Sandoz could obtain FDA approval and launch a generic canagliflozin product before expiration of the asserted patent estate.

What was the litigation timeline?

Date or period	Event
2017	Sandoz filed an ANDA for generic canagliflozin and provided a Paragraph IV certification
2017	Mitsubishi Tanabe filed Civil Action No. 3:17-cv-05319 in the District of New Jersey
2017-2018	Pleadings, patent-infringement contentions, invalidity defenses, and discovery proceeded
2018-2019	The parties litigated claim construction and merits issues associated with the asserted canagliflozin patent rights
2019	The action was resolved and terminated without a reported trial judgment on validity or infringement

The docket designation FLW-DEA identifies District Judge Freda L. Wolfson and Magistrate Judge Douglas E. Arpert.

What was the outcome of Mitsubishi Tanabe v. Sandoz?

The case did not produce a reported final judgment holding the asserted patent valid and infringed, or invalid and not infringed. The docket reflects resolution of the dispute rather than a public merits determination after trial.

The settlement terms were not fully disclosed in the publicly available judicial record. As a result, the case does not establish a public, judicially determined launch date for Sandoz’s generic product.

The absence of a merits opinion limits the precedential value of the case. It does not provide a binding ruling on:

• The validity of the asserted canagliflozin claims.
• The construction of disputed claim terms.
• Whether Sandoz’s specific formulation infringed.
• The scope of Mitsubishi Tanabe’s composition claims.
• The enforceability of the broader Invokana patent estate.

Did Sandoz obtain an authorized generic or early-launch right?

The public case record does not establish a detailed commercial settlement structure, including whether the agreement contained:

• An agreed generic entry date.
• A license tied to a specific patent expiration date.
• An authorized-generic arrangement.
• A supply or manufacturing agreement.
• A contingent launch provision based on patent invalidation.
• A no-launch or delayed-launch covenant.

Because the judicial docket does not disclose complete settlement terms, no precise Sandoz entry date should be inferred solely from the case termination.

A Hatch-Waxman settlement may resolve the litigation while preserving patent protection for a defined period. The settlement can also permit launch before the latest patent expiration if the generic company receives a license. Without the agreement or a regulatory approval record tied to Sandoz’s ANDA, the litigation docket alone cannot establish the commercial terms.

What was the Orange Book status of the canagliflozin patents?

The relevant canagliflozin products were listed in the FDA Orange Book. Orange Book listings for Invokana and related combination products covered multiple patent categories, including:

• Active-ingredient and compound protection.
• Crystalline or solid-state forms.
• Pharmaceutical compositions.
• Combination products containing canagliflozin and metformin.
• Method-of-use claims for diabetes treatment and glycemic control.

Orange Book status must be assessed product by product. A patent listed for Invokana does not necessarily apply to Invokamet or Invokamet XR, and a patent listed for a combination product may not block a standalone canagliflozin ANDA.

The principal regulatory distinction is:

Product	Active ingredients	Patent analysis
Invokana	Canagliflozin	Core canagliflozin composition and use patents
Invokamet	Canagliflozin and metformin	Combination and formulation patents may apply
Invokamet XR	Canagliflozin and extended-release metformin	Extended-release formulation and combination claims may create separate barriers

FDA approval timing also depends on the ANDA’s certifications to every listed patent, not only the patent asserted in a particular civil action.

How strong was Mitsubishi Tanabe’s patent estate?

Mitsubishi Tanabe’s estate had significant structural strength because it included more than one category of protection. A composition-of-matter patent covering the active compound creates a stronger barrier than a patent limited to a narrow formulation or treatment method.

The estate’s main strengths were:

• Core compound claims covering canagliflozin-related C-glucoside structures.
• Multiple patent families directed to distinct technical features.
• Orange Book listing for commercial canagliflozin products.
• A regulatory framework that delayed approval during Hatch-Waxman litigation.
• Potential coverage of both monotherapy and combination products.

The principal vulnerabilities were typical of pharmaceutical composition patents:

• Prior-art challenges to the claimed C-glucoside structures.
• Obviousness attacks based on related SGLT2 inhibitors.
• Written-description and enablement challenges.
• Claim-construction disputes over chemical substituents and stereochemistry.
• Design-around strategies involving different salts, hydrates, polymorphs, or formulations.

Because the Sandoz case ended without a merits ruling, it did not validate or invalidate the asserted claims in a precedential way.

What generic-entry risks existed for Invokana?

The commercial risk depended on the interaction among three factors:

1. The scope and enforceability of the core composition patent.
2. Additional Orange Book-listed patents for the specific dosage form.
3. The terms of any private settlement between Mitsubishi Tanabe and Sandoz.

A generic company could pursue several launch pathways:

Launch pathway	Business effect
Entry after all relevant patents expire	Lowest litigation risk, but latest market entry
Licensed entry under settlement	Earlier entry with agreed restrictions
At-risk launch after a favorable court ruling	High damages and injunction exposure
Launch after noninfringement certification	Depends on the precise product design
Paragraph III approval	FDA approval deferred until patent expiration

For a canagliflozin generic, the principal exposure was not limited to the ’202 patent. Combination products and modified-release presentations could face separate patents even if the core compound patent were overcome.

What litigation precedent did the case create?

The case created limited public precedent because it was resolved without a reported final merits decision. Its practical significance was procedural and commercial:

• It confirmed that Mitsubishi Tanabe actively enforced its canagliflozin rights against generic applicants.
• It demonstrated that Sandoz was willing to pursue a Paragraph IV pathway for canagliflozin.
• It preserved the commercial value of settlement as a mechanism for controlling generic entry.
• It did not resolve the validity of U.S. Patent No. 8,513,202 for future challengers.
• It did not determine whether a particular generic canagliflozin formulation would infringe.

Later ANDA applicants therefore could not treat the Sandoz resolution as a binding ruling on the patent estate.

What does the case mean for licensing, manufacturing, and freedom to operate?

A company seeking to manufacture or commercialize canagliflozin products would need to evaluate more than the original compound patent. The relevant freedom-to-operate analysis would include:

• API synthesis and intermediates.
• Solid-state forms and crystallization processes.
• Tablet composition and excipients.
• Combination with metformin.
• Extended-release delivery systems.
• Labeling for patented methods of treatment.
• Manufacturing know-how and regulatory exclusivity.
• License restrictions imposed through collaboration agreements.

Mitsubishi Tanabe’s original compound rights were commercially important, but downstream formulation and process patents could create separate barriers. A noninfringing API process would not necessarily avoid infringement by a formulation patent, and a noninfringing formulation would not eliminate risk from method-of-use claims.

Key Takeaways

• Mitsubishi Tanabe v. Sandoz was a Hatch-Waxman dispute involving generic canagliflozin.
• The case was filed in 2017 in the District of New Jersey under No. 3:17-cv-05319-FLW-DEA.
• U.S. Patent No. 8,513,202 was a principal patent associated with the dispute.
• Sandoz challenged Mitsubishi Tanabe’s patent rights through an ANDA Paragraph IV pathway.
• The action ended without a reported trial judgment on infringement or validity.
• Public docket materials do not establish complete settlement terms or a definitive Sandoz launch date.
• The broader canagliflozin estate included compound, formulation, combination-product, and method-of-use protection.
• The case had limited precedential value but carried significant commercial importance for generic entry into the Invokana market.

FAQs About Mitsubishi Tanabe v. Sandoz

What was the drug in Mitsubishi Tanabe Pharma Corporation v. Sandoz?

The case concerned canagliflozin, the active ingredient in Invokana and in the combination products Invokamet and Invokamet XR.

Was U.S. Patent No. 8,513,202 invalidated?

No. The case ended without a reported merits ruling invalidating the patent.

Did Sandoz win the patent case?

There was no reported merits victory for Sandoz. The litigation was resolved without a public trial judgment determining that the patent was invalid or not infringed.

Did Mitsubishi Tanabe obtain an injunction against Sandoz?

The public case record does not show a final merits injunction issued after trial. The dispute was resolved through termination of the action.

When could generic canagliflozin enter the U.S. market?

The case docket does not establish a definitive Sandoz launch date. Any authorized or licensed entry date would depend on the confidential settlement and the remaining Orange Book patents applicable to the specific product.

References

1. U.S. District Court for the District of New Jersey. (2017). Mitsubishi Tanabe Pharma Corporation v. Sandoz Inc., No. 3:17-cv-05319-FLW-DEA. PACER docket.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,513,202: C-glucoside derivative. U.S. Department of Commerce.

4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

5. Hatch-Waxman Amendments, Pub. L. No. 98-417, 98 Stat. 1585 (1984).